Letter to the editor regarding: "Development of the ProPal-COPD tool to identify patients with COPD for proactive palliative care"

Authors’ reply RG Duenk,1 C Verhagen,1 EM Bronkhorst,2 RS Djamin,3 GJ Bosman,4 E Lammers,5 PNR Dekhuijzen,6 KCP Vissers,1 Y Engels,1 Y Heijdra6 1Department of Anesthesiology, Pain and Palliative Medicine, 2Department of Health Evidence, Radboud University Medical Center, Nijmegen, 3Department of Res...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of chronic obstructive pulmonary disease Vol. 12; pp. 2731 - 2734
Main Authors Almagro, Pere, Martinez Camblor, Pablo
Format Journal Article
LanguageEnglish
Published New Zealand Dove Medical Press Limited 01.01.2017
Dove Medical Press Ltd
Dove Medical Press
Subjects
Anesthesiology
Chronic illnesses
Chronic obstructive pulmonary disease
COPD Paliative Care
Dyspnea
Hospitals
Humans
Letter
Medical prognosis
Medicine
Mortality
Palliative Care
Patient Comfort
Patients
Pulmonary Disease, Chronic Obstructive
Systematic review
Verbal communication
Netherlands
Online AccessGet full text

Cover

More Information
Summary:Authors’ reply RG Duenk,1 C Verhagen,1 EM Bronkhorst,2 RS Djamin,3 GJ Bosman,4 E Lammers,5 PNR Dekhuijzen,6 KCP Vissers,1 Y Engels,1 Y Heijdra6 1Department of Anesthesiology, Pain and Palliative Medicine, 2Department of Health Evidence, Radboud University Medical Center, Nijmegen, 3Department of Respiratory Medicine, Amphia Hospital, Breda, 4Department of Respiratory Medicine, Slingeland Hospital, Doetinchem, 5Department of Respiratory Medicine, Gelre Hospitals, Zutphen, 6Department of Pulmonary Diseases, Radboud University Medical Center, Nijmegen, the Netherlands We thank Dr Almagro and Dr Martinez Camblor for their letter to the editor in response to our manuscript entitled “Development of the ProPal-COPD tool to identify patients with COPD for proactive palliative care”.1 We are pleased that both the authors agree with us on the importance of proactive palliative care (PPC) in COPD as well as its underutilization in this patient group. We also fully support their view that PPC should not be limited to the terminal phase of chronic diseases such as COPD but that it can be delivered alongside standard therapies, according to the needs and preferences of patients. View the original paper by Duenk and colleagues.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Commentary-1
ISSN:1178-2005
1176-9106
1178-2005
DOI:10.2147/COPD.S148601